CD204+ TAMs located in the tumor stroma area were also identified as useful prognostic markers in non-small-cell lung cancer (NSCLC) (70) and an increased number of CD204+ TAMs was positively associated with worse clinical prognoses in breast cancer, including relapse-free survival, distant relapse-free survival and breast cancer-specific survival (71). This evidence concerns the gene MSR1 and breast carcinoma.